XII. 1 Chronic Diseases (Diabetes, Obesity, etc.)

Type 2 diabetes, obesity, and metabolic syndrome reshape the gut ecosystem, while the microbiota feeds back on insulin sensitivity and inflammation.

How Metabolic Conditions Reshape Your Gut Microbiota

Chronic metabolic conditions such as type 2 diabetes, obesity, and metabolic syndrome change the internal environment in which gut microbes live [111] [531].

The bidirectional relationship between gut microbiota^[G] and metabolic disease was established most dramatically by a series of fecal microbiota transplant experiments conducted between 2006 and 2013. Ridaura and colleagues (Washington University, 2013, Science) transplanted gut microbiota from obese and lean human twins into germ-free^[G] mice. Mice receiving obese donor microbiota gained significantly more fat mass than those receiving lean donor microbiota, despite consuming the same diet under identical conditions. The phenotype was transferable, demonstrating that the obese-associated microbiota could drive metabolic dysfunction independently of host genetics or dietary intake. [552] The earlier work by Cani and colleagues (2007, Diabetes) established the endotoxemia hypothesis: high-fat diet feeding in mice increased intestinal permeability^[G], elevating circulating bacterial LPS by 2- to 3-fold. This "metabolic endotoxemia" was sufficient to produce obesity, insulin resistance, and adipose tissue inflammation even in the absence of excess caloric intake, mediated through TLR4-dependent innate immune activation. [531] The mechanistic picture that emerged from these and subsequent studies identified several microbiota-dependent pathways contributing to metabolic disease: reduced butyrate (a short-chain fatty acid that is the primary energy source for colonocytes) (a short-chain fatty acid^[G] that nourishes colon cells and reduces inflammation) production impairing gut barrier integrity, altered bile acid metabolism affecting glucose homeostasis, modified branched-chain amino acid metabolism increasing insulin resistance, and LPS-mediated chronic low-grade inflammation driving adipose tissue dysfunction. [111] For clinical management, these pathways indicate that gut microbiota optimization – through dietary fiber, fermented foods, prebiotic supplementation, and lifestyle interventions – is not an adjunct to metabolic disease treatment but a mechanistically relevant primary target. FMT studies in type 2 diabetes and metabolic syndrome have produced mixed but increasingly promising results, with responders showing durable microbiota shifts and improved insulin sensitivity.

Blood glucose patterns, bile acid flow, gut motility, and immune tone shift over time, and the microbiota adapts to that new physiology. For patients, this helps explain why metabolic disease can come with digestive symptoms and why “metabolism” and “gut health” often move together [459].

Across many studies, people with obesity or type 2 diabetes often show microbiota patterns consistent with a more inflammatory intestinal setting. This may include a relative decrease in taxa linked with mucus support and anti-inflammatory metabolite production, such as Akkermansia muciniphila and Faecalibacterium prausnitzii^[G], although the direction and strength of these changes vary across individuals.

Another recurring observation is a relative expansion of groups that tolerate inflammatory pressure, including members of Enterobacteriaceae. In clinical terms, this usually reflects ecological stress rather than a classic infection. When the intestinal environment becomes more oxidative and inflamed, microbes that can thrive under those conditions gain a competitive advantage.

Low-grade inflammation can also affect microbial function. Shifts in substrate availability and bile acid signaling may reduce the relative contribution of short-chain fatty acid producers, while favoring pathways that maintain inflammation and barrier strain. A weakened barrier may allow microbial components to enter the circulation more easily, contributing to insulin resistance and persistent inflammatory signaling.

Medications commonly used in metabolic disease further shape the ecosystem. Metformin is a well-known example: it can alter microbial composition and function, and some of its metabolic benefits may partly involve gut-based pathways. Other drugs can also influence the microbiota, but the direction is less predictable and often depends on baseline community structure and diet.

Diet remains one of the strongest levers because it changes what microbes can use as fuel. Diets high in refined carbohydrates and saturated fats tend to favor communities associated with inflammatory signaling, while fiber-rich meals support microbial metabolism that produces acetate, propionate, and butyrate. These metabolites are linked with gut barrier regulation and metabolic signaling, even though they do not “cure” disease on their own.

Physical activity adds another practical mechanism. Regular movement improves insulin sensitivity and can change transit time and appetite regulation, indirectly shaping microbial growth conditions. In many patients, consistent exercise aligns with better metabolic control and fewer gut-related complaints, even if weight loss is modest.

The relationship between metabolic disease and microbiota is therefore two-way: altered metabolism and inflammation reshape the microbial ecosystem, and the ecosystem can reinforce the same metabolic patterns. The clinical goal is not to chase a single “perfect” bacterium, but to reduce inflammatory pressure, support barrier function, and improve metabolic flexibility through realistic interventions.

When patients understand this loop, treatment becomes more coherent. Managing metabolic disease is still about glucose, lipids, and cardiovascular risk–but it also includes supporting the gut ecosystem with nutrition, appropriate medication choices, sleep, and activity, because these factors influence the same biological system from different angles.

MASLD and the Gut–Liver Axis – 2024 Clinical Frame

The MASLD^[G] (metabolic dysfunction-associated steatotic liver disease) nomenclature introduced by the 2023 AASLD/EASL/ALEH Delphi consensus marks the 21st century's most prevalent metabolic epidemic – affecting an estimated 25–30% of adults in many populations. The gut–liver axis plays a central role in MASLD pathogenesis: increased intestinal permeability^[G] enables LPS translocation, fueling chronic low-grade inflammation and hepatic insulin resistance [710], [711]. Microbiota-derived secondary bile acids (DCA, LCA) modulate hepatocyte metabolism through FXR^[G] and TGR5^[G] receptors; in MASLD patients, reduced butyrate-producing taxa and enriched ethanol-producing Klebsiella strains are documented. Tilg et al. (Cell Metabolism, 2022) provides the clinical framework for microbiome-targeted MASLD therapies: prebiotic fiber, polyphenol intake, and FMT pilot trials in selected cases [711].

Modernized T2D Microbiome Narrative – Metformin as a Confounder

Cross-sectional studies from the 2010s ("reduced Akkermansia in T2D patients") initially appeared to suggest a causal microbiome association. In their 2015 Nature paper, Forslund and colleagues re-analysed 784 human gut metagenomes from Danish, Swedish, and Chinese cohorts and disentangled metformin-driven from T2D-intrinsic microbiota signatures: a large part of the differences previously believed to be T2D-specific turned out to be metformin effects – among them the relative enrichment of Escherichia species (which also relates to the drug's known gastrointestinal side effects) and an increase in short-chain fatty acid producing capacity, through which the microbiota mediates the therapeutic effect of metformin [174]. This reframes the prior literature: many well-known features of the "T2D microbiome" are drug effects, not disease-specific. An important limitation is that the study is based on cross-sectional metagenomic data rather than longitudinal follow-up. Clinical implication: microbiome assessment in T2D patients must account for medication history (particularly metformin, PPIs, statins) to distinguish the true pathological pattern.

GLP-1 Agonists and the Microbiome – A Bidirectional Interaction

The clinical success of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) raises a biological question: is the effect purely direct receptor agonism, or does the microbiome contribute? The available evidence is still largely preclinical: in a high-fat-diet mouse model, semaglutide improved body weight and glucose parameters while also altering gut microbiota composition and microbial metabolic pathways [246]. Gut–liver axis reviews explicitly frame incretin-based drugs as agents that interact with microbiota, bile acid and SCFA signalling – but the direction of causality (does the drug reshape the microbiota, or does the baseline microbiota shape the drug response?) has not been resolved in humans [711]. No randomised human trial currently settles this bidirectional interaction. Clinical relevance: inter-individual variability in GLP-1 agonist efficacy plausibly reflects baseline microbiome state in part – but this remains a hypothesis, not an established relationship; fiber intake and microbiome support are well-founded lifestyle measures that complement pharmacotherapy in their own right.

FMT for Insulin Resistance / Obesity

The durability of metabolic FMT is limited: in the randomised trial by Kootte and colleagues (Cell Metabolism, 2017), allogeneic FMT from lean donors significantly improved insulin sensitivity in patients with metabolic syndrome at 6 weeks, but this effect was no longer detectable at 18 weeks, and the magnitude of the response was predicted by baseline gut microbiota composition (low baseline diversity) [712]. Clinical message: metabolic FMT is not a stand-alone intervention but a lifestyle anchor; its indications remain limited and it is to be performed within clinical trial frameworks.

How to Modulate Microbiota Amidst Chronic Diseases

A diet centered on natural, fiber-containing foods is viewed as the main tool for supporting microbial functions in metabolic conditions [459].

Polyphenol-rich ingredients such as berries, herbs, and green tea are considered helpful in shaping microbial metabolic pathways and oxidative balance.

Regular intake of soluble fibers and resistant starch is thought to encourage the production of short-chain fatty acids that communicate with the gut barrier and immune system.

Consistent moderate physical activity contributes to better intestinal transit and metabolic signaling, indirectly influencing microbial networks.

Reducing highly processed foods may limit exposures that disturb barrier integrity and microbial stability.

Fermented foods can provide living microorganisms and metabolites that enrich the daily microbial environment.

Attention to meal composition and timing helps avoid repeated glycemic peaks that stress both metabolism and the microbiota.

Stress-management practices are increasingly recognized as modulators of the gut–brain dialogue that affects microbial balance.

Careful and justified use of antibiotics is important, as unnecessary courses can destabilize an already vulnerable ecosystem.

Evaluating changes in body composition and metabolic markers offers a more meaningful picture than weight alone when judging progress.

Microbiota Effects

• Metabolic disorders are linked with functional shifts in the gut ecosystem rather than a single universal pattern [552] [531].
• Relative reduction of SCFA-producing taxa, including Faecalibacterium prausnitzii, is frequently observed and relates to barrier strain [531] [111].
• Expansion of Enterobacteriaceae often reflects an inflammatory and oxidative intestinal milieu.
• Beneficial mucin-associated species such as Akkermansia muciniphila may decline in many patients.
• Gut permeability changes can allow microbial components (e.g., LPS) to enhance systemic immune activation.
• Microbiota influences bile acid transformation, shaping metabolic and hormonal signaling.
• The ecosystem includes bacteriophages^[G], Candida species, and occasional archaea, modulating bacterial networks.
• Metformin therapy commonly induces microbial and metabolite shifts linked to glucose control.
• Physical activity alters transit time and lactate-utilizing pathways (e.g., Veillonella → propionate).
• Reduced production of butyrate and propionate is associated with mucosal vulnerability.
• Diet rich in fermentable fibers promotes SCFA-mediated gut–immune communication.
• Microbiota-centered approaches are being studied as adjuncts in obesity and type 2 diabetes care.

Patient Guidance

• Choose a fiber-rich, largely plant-based diet to support gut microbial functions and SCFA production.
• Do moderate aerobic activity most days (such as brisk walking or cycling) to help metabolic and intestinal balance.
• Reduce ultra-processed foods and ingredients that may irritate the gut barrier.
• Include fermented foods like yogurt, kefir, or sauerkraut several times per week if well tolerated.
• Plan carbohydrates with protein and healthy fats to avoid large glucose peaks.
• Use stress-management routines to support the gut–brain connection.
• Take antibiotics only when clearly indicated by your doctor.
• Discuss any prebiotic or probiotic supplements with a healthcare professional before starting.
• Follow body composition and metabolic markers, not weight alone.
• Remember: microbiota care is a long-term habit, not a quick reset.

References

[111] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016. Link

Mechanistic review of short-chain fatty acids (SCFAs), produced by bacterial fermentation of dietary fibre. Fermentable fibre is the primary energy source for the colonic microbiota; the main fermentation products are **acetate, propionate and butyrate**. **Butyrate is the principal energy substrate of colonocytes**; SCFAs also influence barrier integrity, immune function and, once in the circulation, host metabolism, partly via G-protein-coupled receptors (GPR41/43) and histone deacetylase inhibition. This entry is the source for the textbook-level claims of III.2 (S-0302-01, -02). Important: a **review**, not original experimental data.

[174] Forslund K, Hildebrand F, Nielsen T et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015. Link

Using 784 human gut metagenomes, this study disentangled type 2 diabetes (T2D) microbiome signatures from antidiabetic drug effects and showed antidiabetic medication, particularly metformin, confounds prior T2D dysbiosis associations. The authors provide evidence for microbial mediation of metformin's therapeutic effects through short-chain fatty acid production, and for microbiota-mediated mechanisms behind known GI side effects, including a relative increase in Escherichia species. The findings highlight that treatment status must be controlled when characterizing disease-associated microbiomes.

[246] Sun L, Shang B, Lv S, Liu G, Wu Q, Geng Y. Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice. Front Pharmacol. 2025. Link

A preclinical experiment in male C57BL/6J mice testing how semaglutide, a GLP-1 receptor agonist, affects metabolism and the gut microbiota in diet-induced obesity, and whether its benefits can be passed on by faecal microbiota transplantation. Animals received a standard diet, a high-fat diet, or a high-fat diet plus semaglutide; faecal suspension supernatant and faecal bacteria from the semaglutide group were then transplanted into antibiotic-treated pseudo-germ-free recipients. Semaglutide reduced body weight, body fat, fasting blood glucose and insulin levels and improved insulin resistance and sensitivity, acting through lipid-metabolism genes in liver and adipose tissue and appetite-regulating genes in the hypothalamus; body weight rebounded markedly four weeks after the drug was stopped. Transplantation transferred part of the benefit to recipient mice, and both semaglutide and the transplant reshaped the composition of the faecal microbiota and altered serum pathways such as amino acid and pyrimidine metabolism, with the bacterial fraction rather than the supernatant appearing to be decisive. This is animal evidence, so its relevance to human treatment is not established and any claim built on it should be handled as a hypothesis rather than as a clinical fact.

[459] Sonnenburg JL, Bäckhed F. Diet–microbiota interactions as moderators of human metabolism. Nature. 2016. Link

Review of mechanisms linking the gut microbiota to obesity and type 2 diabetes drawing on translational animal models and human studies. The microbiota emerges as a mediator of dietary impact on host metabolic status, with growing efforts to establish causal relationships in people and develop therapeutic interventions including personalised nutrition.

[531] Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007. Link

Bacterial lipopolysaccharide (LPS) is identified as a triggering factor for insulin resistance, obesity and diabetes. Plasma LPS fluctuates with feeding/fasting and a 4-week high-fat diet chronically increased it 2-3-fold ("metabolic endotoxemia") while increasing the proportion of LPS-containing gut microbiota. Inducing comparable metabolic endotoxemia in mice via continuous subcutaneous LPS infusion for 4 weeks reproduced the high-fat-diet phenotype: increased fasting glycaemia and insulinaemia, weight gain, adipose F4/80+ inflammation, and hepatic triglyceride accumulation.

[552] Ridaura VK, Faith JJ, Rey FE et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013. Link

Faecal microbiota from adult female twin pairs discordant for obesity was transplanted into germ-free mice fed mouse chow and US-style diets. Increased body and fat mass and obesity-associated metabolic phenotypes were transmissible by both uncultured and cultured fecal communities. Cohousing obese-microbiota mice with lean-microbiota cage mates prevented obesity development, with rescue driven by invasion of specific Bacteroidetes from lean into obese microbiota. The effect was diet-dependent, revealing rapid, transmissible and modifiable diet-by-microbiota interactions in body composition.

[710] Vallianou, N. G., Kounatidis, D., Psallida, S., et al. NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options. Metabolites. 2024. Link

A comprehensive review of the gut-liver axis in NAFLD/MASLD pathogenesis and treatment. The authors describe how increased intestinal permeability and bacterial (LPS) translocation drive chronic low-grade inflammation and hepatic insulin resistance, and survey microbiome-targeted therapeutic options (probiotics, FMT, diet).

[711] Tilg H, Adolph TE, Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications. Cell Metabolism. 2022. Link

Tilg, Adolph and Trauner's 2024 Cell Metabolism review synthesises current understanding of the gut–liver axis and its clinical implications for metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH (formerly NAFLD/NASH). The authors detail mechanisms by which gut microbiota, intestinal barrier permeability, bile acids, microbial metabolites (SCFAs, ethanol, TMAO, BAs) and portal lipopolysaccharide flux drive hepatic steatosis, inflammation, fibrosis and HCC progression. Key dysbiotic patterns and beneficial taxa (Akkermansia, Faecalibacterium) are catalogued. Therapeutic strategies discussed include dietary intervention, FMT, microbiota-targeted drugs, FXR agonists (resmetirom for MASH), and GLP-1 agonists. The review is a comprehensive 2024 update on hepatology-microbiome translation.

[712] Kootte R, Levin E, Salojärvi J, Smits L, Hartstra A, Udayappan S, Hermes G, Bouter K, Koopen A, Holst J, Knop F, Blaak E, Zhao J, Smidt H, Harms A, Hankemeijer T, Bergman J, Romijn H, Schaap F, Olde Damink S, Ackermans M, Dallinga-Thie G, Zoetendal E, de Vos W, Serlie M, Stroes E, Groen A, Nieuwdorp M. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell metabolism. 2017. Link

Baseline microbiota composition determines who responds favorably to FMT in metabolic syndrome — Allogenic FMT improved insulin sensitivity at 6 weeks; the effect did not persist at 18 weeks. Response correlates with baseline low microbiota diversity. Plasma metabolites (GABA) changed. Mechanism-revealing follow-up to the Vrieze 2012 trial.